The Servier Group agreed to acquire CStone Pharmaceuticals, Exclusive rights to TIBSOVO® in Greater China and Singapore from CStone Pharmaceuticals (SEHK:2616) for $44 million on December 21, 2023. This will be followed by a payment of up to 6 million USD upon completion of the transition. As a result, the licensing agreement with Servier will be terminated and CStone will be released from payment obligations of any remaining development and commercialization milestones.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.09 HKD | +23.86% | +26.74% | -51.98% |
08:38am | Non-Executive Director Increases Shareholding in CStone Pharma; Shares Surge 25% | MT |
Apr. 29 | Cstone Pharmaceuticals’ CEO Boosts Stakeholding | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.98% | 143M | |
-0.94% | 104B | |
+6.79% | 97.47B | |
+5.71% | 22.25B | |
-12.83% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.32% | 16.36B | |
+8.34% | 14.39B | |
+39.54% | 12.37B |
- Stock Market
- Equities
- 2616 Stock
- News CStone Pharmaceuticals
- The Servier Group agreed to acquire CStone Pharmaceuticals, Exclusive rights to TIBSOVO® in Greater China and Singapore from CStone Pharmaceuticals for $44 million.